![](https://media.asiaone.com/sites/default/files/styles/a1_600x316/public/original_images/Jul2024/pr-newswire_500_4_2232.jpg?h=7de12b8a&itok=iao2mKgP)
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and ...
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL …